ArticleScientific reports2024
A drug-drug co-amorphous system for highly improved solubility of breviscapine: an experimental and computational study.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Co-Amorphous Ursolic Acid-Quercetin Complex Improves Solubility and In Vivo Expectorant-Antitussive Activity.Plants (Basel, Switzerland) · 2026Article
- Co-amorphization for solubility and dissolution rate improvement: the case of low-crystallization-tendency drugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Crystal engineering for poorly water-soluble drugs: From design to applications.Acta pharmaceutica Sinica. B · 2026Review
- Dissolution Rate and Stability Improvement of Hydrochlorothiazide and Valsartan by Co-Amorphous Formulation.Advances in pharmacological and pharmaceutical sciences · 2026Article
- Co-amorphous Approach for Enhancing Rilpivirine Oral Bioavailability using CYP3A4 Inhibitor as a Co-former.AAPS PharmSciTech · 2025Article
- The Development and Characterization of Layered Pellets Containing a Combination of Amorphized Amlodipine Besylate and Hydrochlorothiazide Using a High-Shear Granulator.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
Drug-drug co-amorphous systems are a promising approach to improve the aqueous solubility of poorly water-soluble drugs. This study explores the combination of breviscapine (BRE) and matrine (MAT) form an amorphous salt, aiming to synergistically enhance the solubility and dissolution of BRE. In silico analysis of electrostatic potential and local ionization energy were conducted on BRE-MAT complex to predict the intermolecular interactions, and solvent-free energies were calculated using thermodynamic integration and density functional theory. The co-amorphous mixture, prepared by solvent evaporation, was characterized using various analytical techniques, including polarized microscopy, differential scanning calorimetry, and powder X-ray diffraction, confirming its amorphous nature. Fourier transform infrared spectroscopy and molecular dynamic simulations revealed strong hydrogen bonding, with a proton transfer from the carboxyl group of BRE to the tertiary amine nitrogen of MAT. The resulting co-amorphous salt demonstrated substantial solubility improvement (> 8000-fold in water) and enhanced in vitro dissolution of BRE. The study also confirmed that the co-amorphous salt maintained physical stability at 40 °C and 75% relative humidity over 6 months. These findings provide a viable strategy for developing drug-drug co-amorphous formulations to enhance solubility and stability, with significant potential for pharmaceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.